Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More
26. November 2024 11:44 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target...
Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period
22. November 2024 07:14 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030" report has been added to ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
07. November 2024 08:30 ET
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Antibody Drug Conjugates (ADC) Industry Report 2024 - Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
05. November 2024 05:31 ET
|
Research and Markets
Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates (ADC) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Antibody...
Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche., Daiichi Sankyo, Pfizer, and Gilead Sciences
04. November 2024 07:00 ET
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global sales of ADCs on...
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030
31. Oktober 2024 12:57 ET
|
Research and Markets
Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ...
Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24. Oktober 2024 10:12 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides...
Bispecific Antibody Drug Conjugates Market Opportunity Outlook 2024-2029: China Leads Over 35 Candidates, Key Companies Pioneering BsADC are Amgen, Innovent Biologics, AstraZeneca
14. Oktober 2024 05:52 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to...
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 Players - ADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More
09. Oktober 2024 10:13 ET
|
Research and Markets
Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report by Component, Target, Application, End-user, and Region 2024-2032" report has been added to ...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14. September 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...